Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jan 22, 2021 4:18pm
140 Views
Post# 32362049

RE:RE:RE:RE:RE:Getting a Green Light rather than a Yellow Light from FDA

RE:RE:RE:RE:RE:Getting a Green Light rather than a Yellow Light from FDA My take is progressively every time  they address the NASH trial they sound more confident for instance in the previous CC the CEO was stating they know the drug is working and want to get the chance to proove it, the PR states they got the formal positive response from FDA with the recommendation to discus the trial's design and yesterday he hinted it is fine details which needs to be adjusted. Based on the change of language they seem to be more certain as the time passes.
Give it what ever colour you want but after all the conversations with agencies, multiple presentations re NASH, the backing of scientists and  getting letter may proceed for Phase 3 not 2b or 2b/3 from FDA it is to me a go.
 
<< Previous
Bullboard Posts
Next >>